Helicobacter pylori therapy: first-line options and rescue regimen
- PMID: 11549823
- DOI: 10.1159/000050668
Helicobacter pylori therapy: first-line options and rescue regimen
Abstract
In the present paper, several points regarding Helicobacter pylori treatment are reviewed, with the following conclusions: (1) all different proton pump inhibitors (PPIs) are equivalent when prescribed with antibiotics; (2) ranitidine bismuth citrate is equal to or, in some cases with antibiotic resistance, more effective than PPI; (3) previous treatment with PPI does not seem to affect the rate of eradication obtained with PPI plus two antibiotics; (4) just 1 week of PPI is enough to obtain duodenal ulcer healing, provided that H. pylori eradication is achieved; (5) the eradication rates seem to be higher in peptic ulcer than in nonulcer dyspepsia; (6) in areas where the prevalence of metronidazole resistance is high, triple therapy including a PPI, clarithromycin, and amoxicillin is the best option, and (7) quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is the recommended second-line therapy after PPI-clarithromycin-amoxicillin failure, although replacing the PPI and the bismuth compound by ranitidine bismuth citrate achieves also good results.
Copyright 2001 S. Karger AG, Basel
Similar articles
-
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.Eur J Gastroenterol Hepatol. 2001 Nov;13(11):1303-7. doi: 10.1097/00042737-200111000-00007. Eur J Gastroenterol Hepatol. 2001. PMID: 11692055 Clinical Trial.
-
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351. World J Gastroenterol. 2015. PMID: 25574111 Free PMC article. Clinical Trial.
-
[new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].Med Clin (Barc). 1998 Jan 17;110(1):1-5. Med Clin (Barc). 1998. PMID: 9527978 Clinical Trial. Spanish.
-
Is it time for quadruple therapy to be first line?Can J Gastroenterol. 2003 Jun;17 Suppl B:33B-35B. doi: 10.1155/2003/303528. Can J Gastroenterol. 2003. PMID: 12905979 Review.
-
Helicobacter pylori eradication therapy.Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25. Future Microbiol. 2010. PMID: 20353303 Review.
Cited by
-
Cloning, polymorphism, and inhibition of beta-carbonic anhydrase of Helicobacter pylori.J Gastroenterol. 2008;43(11):849-57. doi: 10.1007/s00535-008-2240-3. Epub 2008 Nov 18. J Gastroenterol. 2008. PMID: 19012038
-
Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives.Mol Divers. 2010 May;14(2):371-84. doi: 10.1007/s11030-009-9181-5. Epub 2009 Aug 6. Mol Divers. 2010. PMID: 19657719
-
Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci.Antimicrob Agents Chemother. 2002 Dec;46(12):3940-6. doi: 10.1128/AAC.46.12.3940-3946.2002. Antimicrob Agents Chemother. 2002. PMID: 12435699 Free PMC article.
-
Potent gastric acid inhibition in Helicobacter pylori eradication.Drugs. 2005;65 Suppl 1:83-96. doi: 10.2165/00003495-200565001-00012. Drugs. 2005. PMID: 16335862 Review.
-
Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.Antimicrob Agents Chemother. 2005 Aug;49(8):3468-73. doi: 10.1128/AAC.49.8.3468-3473.2005. Antimicrob Agents Chemother. 2005. PMID: 16048962 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical